ASCO 2023 | Zilurgisertib as monotherapy or in combination with ruxolitinib in patients with MF-related anemia
Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of the Phase I/II LIMBER-104 trial (NCT04455841), which is evaluating the safety and activity of the selective ALK2 inhibitor zilurgisertib in patients with myelofibrosis (MF)-related anemia. Dr Bose summarizes the endpoints of this clinical trial, and results have demonstrated that treatment with zilurgisertib monotherapy or in combination with ruxolitinib induces responses in the non-transfusion-dependent patients. Furthermore, a reduction in hepcidin following zilurgisertib dosing was observed in both treatment groups. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
